JP2024537170A5 - - Google Patents

Info

Publication number
JP2024537170A5
JP2024537170A5 JP2024520862A JP2024520862A JP2024537170A5 JP 2024537170 A5 JP2024537170 A5 JP 2024537170A5 JP 2024520862 A JP2024520862 A JP 2024520862A JP 2024520862 A JP2024520862 A JP 2024520862A JP 2024537170 A5 JP2024537170 A5 JP 2024537170A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
nucleic acid
amino acid
encoded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537170A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077610 external-priority patent/WO2023060126A1/en
Publication of JP2024537170A publication Critical patent/JP2024537170A/ja
Publication of JP2024537170A5 publication Critical patent/JP2024537170A5/ja
Pending legal-status Critical Current

Links

JP2024520862A 2021-10-06 2022-10-05 調整可能な養子細胞療法のための操作されたサイトカイン受容体 Pending JP2024537170A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252850P 2021-10-06 2021-10-06
US63/252,850 2021-10-06
PCT/US2022/077610 WO2023060126A1 (en) 2021-10-06 2022-10-05 Engineered cytokine receptors for tunable adoptive cell therapy

Publications (2)

Publication Number Publication Date
JP2024537170A JP2024537170A (ja) 2024-10-10
JP2024537170A5 true JP2024537170A5 (cg-RX-API-DMAC7.html) 2026-05-20

Family

ID=85803736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520862A Pending JP2024537170A (ja) 2021-10-06 2022-10-05 調整可能な養子細胞療法のための操作されたサイトカイン受容体

Country Status (6)

Country Link
US (1) US20240408139A1 (cg-RX-API-DMAC7.html)
EP (1) EP4413029A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537170A (cg-RX-API-DMAC7.html)
AU (1) AU2022361486A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233987A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023060126A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4630446A1 (en) * 2022-12-06 2025-10-15 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof
EP4630043A1 (en) * 2022-12-06 2025-10-15 Dynamic Cell Therapies, Inc. Immune-activating complexes
WO2025039159A1 (en) * 2023-08-21 2025-02-27 Hangzhou Hervor Therapeutics Co., Ltd Synthetic cytokine signaling system, preparation method, and uses thereof
WO2025255267A1 (en) * 2024-06-05 2025-12-11 Dynamic Cell Therapies, Inc. Engineered receptors for activation of regulatory t-cells
WO2026082710A1 (en) * 2024-10-16 2026-04-23 F. Hoffmann-La Roche Ag Small molecule-inducible recombinant receptors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US11248058B2 (en) * 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
AU2016251687C1 (en) * 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN113307864A (zh) * 2015-06-12 2021-08-27 艾希奥美公司 用于产生嵌合多肽的方法和组合物
CN108697798A (zh) * 2016-02-16 2018-10-23 达纳-法伯癌症研究所有限公司 免疫疗法组合物及方法
AU2019227979B2 (en) * 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
WO2019236522A1 (en) * 2018-06-04 2019-12-12 Dana-Farber Cancer Institute, Inc. Compositions and methods for targeted immunotherapy
SG11202100935TA (en) * 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
US20200147137A1 (en) * 2018-11-08 2020-05-14 WUGEN, Inc. Compositions and methods for treatment of cancer
US20230348556A1 (en) * 2019-02-21 2023-11-02 Arbele Limited Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
JP2022525781A (ja) * 2019-03-20 2022-05-19 マサチューセッツ インスティテュート オブ テクノロジー 免疫細胞療法における両親媒性物質の使用およびそのための組成物
EP3881866A1 (en) * 2020-03-16 2021-09-22 GEMoaB GmbH A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated response in a mammal
US20230149465A1 (en) * 2020-04-06 2023-05-18 Celledit Llc Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling
AU2021347320A1 (en) * 2020-09-24 2023-05-11 The Jackson Laboratory Humanized mouse models for assessing immune cell therapy
EP4630043A1 (en) * 2022-12-06 2025-10-15 Dynamic Cell Therapies, Inc. Immune-activating complexes
EP4630446A1 (en) * 2022-12-06 2025-10-15 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof

Similar Documents

Publication Publication Date Title
US7141651B2 (en) Multiple cytokine protein complexes
JP2022502037A5 (cg-RX-API-DMAC7.html)
AU2003228057B2 (en) Immunoconjugates for the treatment of tumours
EP3749372B1 (en) Edb targeting il-12 compositions
US11987609B2 (en) Proteinaceous heterodimer and use thereof
CN114195900A (zh) 一种抗4-1bb/pd-l1双特异性抗体及其用途
WO2015103928A1 (zh) Il-15异源二聚体蛋白及其用途
US20070003514A1 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
EP3843849A1 (en) Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
Mohammadi et al. Immunotherapy For Researchers
JP2024546938A (ja) マルチサブユニットサイトカインを含む二重サイトカイン融合タンパク質
JP2024544972A (ja) Sirp1a及びcd40lベースのキメラタンパク質
CN114746106A (zh) 通过肿瘤中使用il-7融合蛋白增加淋巴细胞数的方法
WO2024193705A1 (en) Tnf superfamily member immunocytokine and uses thereof
CN109414509B (zh) 使用双特异性抗体的抗体药物偶联物平台
JP2025540340A (ja) キメラ抗原受容体
WO2025217954A1 (zh) 抗pd-1抗体与il-2突变体的双功能融合蛋白
EP1731531A2 (en) Multiple cytokine-antibody complexes
WO2021212037A1 (en) Immune cell redirecting compositions and therapeutic uses thereof
JP2023521174A (ja) インターロイキン1受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体
CN116621966B (zh) 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
JP2024527963A5 (cg-RX-API-DMAC7.html)
TW202444742A (zh) 經工程化之il—21變異體及其使用方法
WO2025201438A1 (zh) 一种双融合蛋白及其用途
CN117229397A (zh) 抗cd40抗体及其用途